Drug Profile
Research programme: oxazole compounds - Otsuka Pharmaceutical
Alternative Names: 453150; PDE4 inhibitors - Otsuka PharmaceuticalLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class
- Mechanism of Action Tumour necrosis factor alpha inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in Japan (Transdermal)